Global Neurology Academy

The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.

For more information about GNA, visit www.globalneurologyacademy.org.

403

LikeLikedUnlike

Episodes 151-165 of 183

AI in Neurology: What Tools Are Emerging?
NeuroFrontiers
AI in Neurology: What Tools Are Emerging?
- Jerome Lisk, MD, MBA, M.S., FAAN
  Peer
- Mark Mintz, MD
  Peer
Investigating the Link Between Hypertension Medications & Dementia
NeuroFrontiers
Investigating the Link Between Hypertension Medications & Dementia
- Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
  Peer
- Zachary Marcum, PharmD, PhD
  Peer
B-Cell Therapy: When Is It Right for Our MS Patients?
NeuroFrontiers
B-Cell Therapy: When Is It Right for Our MS Patients?
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Andrew Chan, MD
  Peer
Alzheimer’s Disease: What’s The Latest Research?
NeuroFrontiers
Alzheimer’s Disease: What’s The Latest Research?
- Jerome Lisk, MD, MBA, M.S., FAAN
  Peer
- Peter Whitehouse, MD, PhD
  Peer
- Daniel George, MSc, PhD
  Peer
Diving into the Debate Surrounding Aducanumab for Alzheimer’s
NeuroFrontiers
Diving into the Debate Surrounding Aducanumab for Alzheimer’s
- Jerome Lisk, MD, MBA, M.S., FAAN
  Peer
- Peter Whitehouse, MD, PhD
  Peer
Investigating the Impact of Mobile Stroke Units
NeuroFrontiers
Investigating the Impact of Mobile Stroke Units
advertisement
Investigating the Potential Link Between Epstein-Barr Virus & MS
NeuroFrontiers
Investigating the Potential Link Between Epstein-Barr Virus & MS
Keys to Closing the Gender Gap in Stroke Trials
NeuroFrontiers
Keys to Closing the Gender Gap in Stroke Trials
- Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
  Peer
- Cheryl Carcel, MD, PhD
  Peer
Diagnosing Mental Illness with the Perspectives Approach
NeuroFrontiers
Diagnosing Mental Illness with the Perspectives Approach
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Margaret Chisolm, MD
  Peer
Could T Cells Lead to New MS Treatments?
NeuroFrontiers
Could T Cells Lead to New MS Treatments?
- Jerome Lisk, MD, MBA, M.S., FAAN
  Peer
- Shivashankar Othy, DVM, PhD
  Peer
Seeking Out Symptoms of Broken Heart Syndrome
NeuroFrontiers
Seeking Out Symptoms of Broken Heart Syndrome
- Jerome Lisk, MD, MBA, M.S., FAAN
  Peer
- Ilan Wittstein, MD
  Peer
The Future of Restoring Functionality in Stroke Survivors
NeuroFrontiers
The Future of Restoring Functionality in Stroke Survivors
- David Weisman, MD
  Peer
- Mijail D Serruya MD,PhD
  Peer
advertisement
Refocusing Our Efforts on Advancing Technology to Help Stroke Survivors
NeuroFrontiers
Refocusing Our Efforts on Advancing Technology to Help Stroke Survivors
- David Weisman, MD
  Peer
- Mijail D Serruya MD,PhD
  Peer
Treatment of Progressive MS: Why, Who, When, How
Global Neurology Academy
Treatment of Progressive MS: Why, Who, When, How
- Giancarlo Comi, MD
  Peer
SPECIAL REPORT: Expert Opinion on New MS Drug Approval
Global Neurology Academy
SPECIAL REPORT: Expert Opinion on New MS Drug Approval
- Prof. Ralf Gold
  Peer